AI Article Synopsis
- The increasing costs of innovative cancer treatments necessitate new financing solutions to ease the burden on healthcare systems.
- The study analyzed the potential health-economic impact of biosimilars, focusing on trastuzumab, rituximab, and G-CSF in the German healthcare system.
- Results show that adopting biosimilars could lead to significant annual savings, potentially freeing up resources to fund new treatments.
Article Abstract
Aim: The introduction of new and innovative treatment options for cancer patients is accompanied by a tremendous increase in healthcare costs. Consequently, new financing approaches are strongly needed to reduce the burden on the healthcare system. The introduction of biosimilars - biological drugs containing the active substance of an already approved reference biological drug - can potentially relieve the burden on healthcare systems. Calculating the costs for three frequently used biosimilars, we simulated the health-economic impact of biosimilars in the real world for the German healthcare system.
Methods: Based on available health-economic analyses, the actual prescription and cost containment potential of biosimilars compared to the originator were calculated exemplarily for the cost-intensive therapies trastuzumab in breast cancer, rituximab in follicular lymphoma and G-CSF in supportive care. Incidence calculations were based e.g. on data from the Robert-Koch-Institution, Munich Cancer Registry, and quality indicators of certified centres. Cost calculation was based on Lauer-Taxe® (official reference for pharmaceutical price information).
Results: The application of biosimilars would generate potential annual savings for the chosen examples of up to 4.9 Mio EUR for rituximab in follicular lymphoma, 40.5 Mio EUR for filgrastim, 56.4 Mio EUR for pegfilgrastim, and between 95.9 and 120.5 Mio EUR for trastuzumab.
Conclusions: The consequent use of biosimilars allows a considerable reduction of overall treatment costs, especially for cost-intensive long-term maintenance treatments and therapies with high incidences. If the option of biosimilar usage is fully exploited, enormous resources could be released within the healthcare system in order to offset financing new innovative therapies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejca.2020.07.037 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The acute effect of high-dose supplemental oxygen on haemodynamics assessed by echocardiography in patients with pulmonary vascular disease living in Quito at 2850 m: a randomized, single-blind, placebo-controlled crossover trial.
Eur Heart J Open
November 2024
Department of Pulmonology, University Hospital Zurich, Rämistrasse 100, 8091 Zurich, Switzerland.
Aims: More than 220 Mio people live at altitudes above 2000 m, many of whom have pre-existing chronic diseases, including pulmonary vascular diseases (PVDs) such as pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH). We investigated the acute effects of high-dose supplemental oxygen on pulmonary haemodynamics assessed by echocardiography in patients with PVD permanently living at 2850 m.
Methods And Results: In a randomized, single-blind, placebo-controlled crossover trial, patients with PVD diagnosed with PAH or CTEPH were allocated to receive 10 L/min supplemental oxygen (FiO ≈ 95%) and placebo air administered via a facial mask with reservoir near their living altitude in Quito at 2850 m (FiO0.
Convolutional neural networks for automatic MR classification of myocardial iron overload in thalassemia major patients.
Eur Radiol
December 2024
Department of Radiology, Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy.
Objectives: To develop a deep-learning model for supervised classification of myocardial iron overload (MIO) from magnitude T2* multi-echo MR images.
Materials And Methods: Eight hundred twenty-three cardiac magnitude T2* multi-slice, multi-echo MR images from 496 thalassemia major patients (285 females, 57%), labeled for MIO level (normal: T2* > 20 ms, moderate: 10 ≤ T2* ≤ 20 ms, severe: T2* < 10 ms), were retrospectively studied. Two 2D convolutional neural networks (CNN) developed for multi-slice (MS-HippoNet) and single-slice (SS-HippoNet) analysis were trained using 5-fold cross-validation.
International publication activity in orthopaedic surgery over a ten-year interval.
Eur J Trauma Emerg Surg
December 2024
Department of Vascular Medicine, University Heart and Vascular Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Purpose: International English language publication activities in orthopaedic surgery comparing the years 2008/09 to 2018/19 were analyzed.
Methods: 20 international journals listed on PubMed were examined. The impact factor (IF) for each journal was determined using the InCites Journal Citation Report.
Advancing fracture management: the role of minimally invasive osteosynthesis in orthopedic trauma care.
Eur J Trauma Emerg Surg
October 2024
Department of Orthopedics and Traumatology, Salzburg University Hospital, Paracelsus Medical University, Salzburg, Austria.
Article Synopsis
- Minimally Invasive Osteosynthesis (MIO) is a technique for orthopedic surgery that aims to provide less invasive treatment for fractures but currently lacks standardized guidelines.
- A study analyzing 57 fractures in 53 patients treated with MIO between March 2017 and January 2022 focused on surgical techniques and outcomes, revealing low complication rates and effective healing.
- The research concluded by establishing general principles for MIO, which can improve surgical efficiency and patient recovery across various types of fractures and locations.
Real-time tilting and twisting motions of ligand-bound states of α7 nicotinic acetylcholine receptor.
Eur Biophys J
February 2024
Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, 277-8561, Japan.
The α7 nicotinic acetylcholine receptor is a member of the nicotinic acetylcholine receptor family and is composed of five α7 subunits arranged symmetrically around a central pore. It is localized in the central nervous system and immune cells and could be a target for treating Alzheimer's disease and schizophrenia. Acetylcholine is a ligand that opens the channel, although prolonged application rapidly decreases the response.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!